As the medtech industry looks forward to 2027, FDA’s reorganization will continue to impact the device center’s operations. Industry can expect to see how application of the QMSR is shaking out, what premarket priorities look like, and how stakeholders continue to grapple with digital health and artificial intelligence in the medtech sector. Our Regulatory Forecast spells out what to look for in the upcoming year.
By Laura DiAngelo, MPH | Oct 22, 2026 5:38 PM EDT
Next year will be a busy year in regulatory intelligence for medtech with a bevy of areas to watch. With MDUFA V wrapping up and Congress set to take up the next iteration of the device user fee programs, lawmakers will be turning their attention to the agency – including its device center – to advance their priorities. CDRH is also working to adapt or build several key regulatory frameworks, including updates to its premarket systems, while also entering the first full year of implementation of the Quality Management System Regulations. At the agency level, while 2025’s reductions in force caused the most news-making structural shakeup in FDA history, administrative overhauls in 2026 herald ongoing re-organization that will continue through 2027. In this Regulatory Forecast, AgencyIQ provides a targeted, concise view of the 2027 happenings that will impact the medtech industry.
MDUFA V, the fifth iteration of the Medical Device User Fee program, is winding down, and will end on Sept. 30, 2027. Work on the upcoming reauthorization of MDUFA VI met several key landmarks in 2026, including wrapping negotiations between agency and industry representatives and publication of the commitment letter. We anticipate transmission of the agreement to the Hill for legislative reauthorization before the January due date.
The agreement will include the agency’s proposed draft legislative text for the actual statutory reauthorization, effectively wiping out MDUFA V and setting new payment rates for the next five program years under MDUFA VI. The commitment letters themselves will be incorporated by reference into the legislative reauthorization via committee report.
However, the biggest thing to watch for 2027 will be legislator proposals and debates on statutory changes to device regulatory frameworks. In the commitment letters, the FDA promises programmatic changes already within the agency’s legal authorities, such as committing to new guidance or to speed up certain timelines. But the user fee reauthorization also provides an opportunity for reforms that require updates to the agency’s statutory scaffolding.
Adjustments to the FDA’s pathways are one such change and a common theme for user fee legislation. For the MDUFA VI cycle, we expect some key pathway modernization themes to emerge. For example, we might see interest in the addition of a technology certification pathway for diagnostics, a change that would likely require statutory action by Congress. Further, there’s interest in Congress codifying some of the agency’s designations, includingthe Safer Technologies Program, an alternative to Breakthrough Device designation for devices that offer meaningful benefits in safety over existing alternatives. The move could support the agency’s use of both Breakthrough and STeP designations for its collaboration projects with the Centers for Medicare and Medicaid Services. Other top areas of interest for legislators going into this user fee cycle relate to digital health and AI, electronic labeling and enhanced focus on the supply chain.
We’ll likely start to see the potential riders for a user fee package starting around February 2027, after the 120th Congress is sworn in. The transmission of the agreements to the Hill will kick off a series of hearings, at which FDA leadership, historically accompanied by center leaders, will discuss their plans, priorities and problem areas for the year ahead. For 2027, keeping an eye which proposals seem to be gaining traction on the Hill will be vital.
With lawmakers on the Hill debating the future of the device user fee program, CDRH will continue apace with its policymaking agenda.
A few years ago, the device center indicated that it was looking to “modernize” its 510(k) pre-market notification pathway and…
This excerpt is just part of the analysis. AgencyIQ subscribers can read the full forecast and follow related regulatory developments through ongoing research and searchable tools.